HIPAA Compliance for Rheumatology Practices: Chronic Disease Management

What makes HIPAA compliance distinct for rheumatology is time and connectivity. Rheumatology is chronic-care medicine — patients with rheumatoid arthritis, lupus, psoriatic arthritis, or vasculitis are often followed for decades, generating one of the longest and most detailed longitudinal records in medicine. Every infusion, lab panel, imaging study, and biologic prescription adds to a file that may span twenty or thirty years, and that record is constantly shared with specialty pharmacies, infusion centers, labs, and disease registries. The breadth and longevity of rheumatology data, and the number of outside parties who see it, are what drive the practice’s HIPAA risk.

Where rheumatology PHI flows

A single biologic therapy can involve the prescribing rheumatologist, a specialty pharmacy, a copay-assistance hub, an infusion suite, and a manufacturer’s patient-support program — each receiving identifiable clinical information to do its part. Frequent lab monitoring for drug toxicity sends PHI to reference labs, and many practices contribute data to quality registries such as the ACR’s RISE registry. Each connection is a place where ePHI leaves your direct control. Specialty pharmacies, infusion vendors, and registry intermediaries that handle identifiable data on your behalf are business associates, and you need a Business Associate Agreement with each one.

Long records raise retention and access stakes

Decades-long charts mean retention obligations, legacy systems, and old data formats all become HIPAA issues. A patient who started a biologic in 2008 may have records in a since-replaced EHR, scanned faxes, and a registry export — all still PHI, all still your responsibility. Role-based access control matters more when records are this deep, because front-desk staff scheduling frequent infusions do not need the full clinical history a rheumatologist relies on. Limiting each role to the minimum necessary information shrinks the damage any single compromised account can do.

The Security Risk Analysis

HIPAA’s Security Rule requires a Security Risk Analysis under 45 CFR § 164.308(a)(1)(ii)(A): an accurate, thorough assessment of the risks to all electronic PHI your practice holds. For rheumatology, that means inventorying not just the EHR but the specialty-pharmacy portals, infusion-management software, lab interfaces, and registry connections that carry patient data, then documenting how each is secured. The SRA is the foundation of compliance and the first thing the Office for Civil Rights asks for after a breach or complaint. Pairing it with a structured HIPAA compliance checklist keeps the follow-through on track.

The proposed 2026 Security Rule update

In December 2024, HHS published a Notice of Proposed Rulemaking that would strengthen the Security Rule with requirements like mandatory encryption, multi-factor authentication, network segmentation, and more frequent risk analyses. The proposal is not final — it is still in rulemaking — and if finalized as written, covered entities would have about 240 days from the effective date to comply. For a data-rich, vendor-connected specialty like rheumatology, those controls would touch many systems at once, which is a strong reason to tighten encryption and access now.

How Medcurity helps

Medcurity helps rheumatology practices run a guided Security Risk Analysis, build an inventory of the many vendors and systems that touch their patients’ long records, manage Business Associate Agreements, and keep audit-ready documentation current. The platform is $499/year (about $42/month) for a single practice, and larger groups or multi-site rheumatology organizations can request a quote. It turns a sprawling, decades-deep data environment into a compliance picture you can actually see and defend.

Frequently asked questions

Are specialty pharmacies and infusion centers business associates of a rheumatology practice?

When they create, receive, maintain, or transmit identifiable patient information on your behalf, yes — they are business associates and require a Business Associate Agreement. Because biologic therapy involves several such partners, rheumatology practices often need more agreements than a typical office.

How long do rheumatology practices have to retain patient records?

HIPAA sets a six-year retention period for its required documentation, but state medical-record laws — often longer, especially for minors — usually govern clinical records. Because rheumatology care spans decades, practices frequently hold records far longer, and all of it remains PHI that must stay protected.

Does contributing to a registry like RISE create HIPAA obligations?

It can. If the data you send is identifiable, the registry or its intermediary is handling PHI on your behalf and a Business Associate Agreement is needed. Fully de-identified contributions that meet HIPAA’s de-identification standard fall outside those requirements.

What should a rheumatology Security Risk Analysis include?

It should cover every system that stores or transmits electronic PHI — the EHR, specialty-pharmacy portals, infusion software, lab interfaces, and registry connections — and document the safeguards and risks for each, as required by 45 CFR § 164.308(a)(1)(ii)(A).